Introduction: The efficacy and safety of atezolizumab versus the efficacy and safety of docetaxel as second-or third-line treatment in patients with advanced NSCLC in the primary (n ¼ 850) and secondary (n ¼ 1225) efficacy populations of the randomized phase III OAK study (respectively referred to as the intention-to-treat [ITT] 850 [ITT850] and ITT1225) at an updated data cutoff were assessed.
, intravenously every 3 weeks until loss of clinical benefit or disease progression, respectively. The primary end point was overall survival (OS) in the ITT population and programmed death-ligand 1-expressing subgroup. A sensitivity analysis was conducted to evaluate the impact of subsequent immunotherapy use in the docetaxel arm on the observed survival benefit with atezolizumab.
Results: Atezolizumab demonstrated an OS benefit versus docetaxel in the updated ITT850 (hazard ratio [HR] ¼ 0.75, 95% confidence interval: 0.64-0.89, p ¼ 0.0006) and the ITT1225 (HR ¼ 0.80, 95% confidence interval: 0.70-0.92, p ¼ 0.0012) after minimum follow-up times of 26 and 21 months, respectively. Improved survival with atezolizumab was observed across programmed death-ligand 1 and histological subgroups. In the immunotherapy sensitivity analysis, the relative OS benefit with atezolizumab was slightly greater in the ITT850 (HR ¼ 0.69) and ITT1225 (HR ¼ 0.74) than the conventional OS estimate. Fewer patients receiving atezolizumab experienced grade 3 or 4 treatment-related adverse events (14.9%) than did patients receiving docetaxel (42.4%); no grade 5 adverse events related to atezolizumab were observed.
Conclusions:
The results of the updated ITT850 and initial ITT1225 analyses were consistent with those of the primary efficacy analysis demonstrating survival benefit with atezolizumab versus with docetaxel. Atezolizumab continued to demonstrate a favorable safety profile after longer treatment exposure and follow-up.
Introduction
The standard of care for patients with pretreated NSCLC has changed with the approval of cancer immunotherapies targeting the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) pathway (e.g., atezolizumab, nivolumab, and pembrolizumab). Atezolizumab is an engineered humanized immunoglobulin G1 monoclonal antibody that targets PD-L1 1 and offers a new treatment option for patients with second-line or later NSCLC. Atezolizumab inhibits the binding of PD-L1 to its receptors PD-1 and B7.1 to restore tumor-specific T-cell immunity. [2] [3] [4] Targeting PD-L1 with atezolizumab may preserve immune homeostasis in normal tissue by leaving the PD-L2/PD-1 interaction intact. 5, 6 PD-L1 is expressed on tumor cells (TCs) and tumor-infiltrating immune cells (ICs) in a variety of cancers, and atezolizumab has demonstrated clinical efficacy against many different tumor types. 1 OAK (NCT02008227) is a randomized phase III study comparing the efficacy and safety of atezolizumab with that of docetaxel in patients with locally advanced or metastatic NSCLC whose disease progressed after prior platinum therapy. 7 Patients were enrolled in OAK regardless of their tumors' PD-L1 expression. The target enrollment was initially 850 patients in the intention-to-treat (ITT) population but was later increased to 1225 to power an overall survival (OS) comparison between treatment arms in the high-PD-L1 subgroup (PD-L1 expression on at least 50% of TCs or at least 10% of ICs [TC3 or IC3 subgroup]). However, after the randomized phase II POPLAR study demonstrated survival benefit with atezolizumab in the ITT population and in patients with low or no PD-L1 expression, 8 the OAK statistical plan was amended to test for differences in OS between treatment arms in the ITT and a broader PD-L1-expressing subgroup (PD-L1 expression on at least 1% of TCs or ICs [TC1/2/3 or IC1/2/3 subgroup]). The initial 850 patients enrolled were sufficient to power this analysis and comprised the primary efficacy population (ITT850), with a final enrollment of 1225 patients (ITT1225).
At the time of the primary OAK analysis (median followup time of 21 months), atezolizumab demonstrated improved OS versus docetaxel (hazard ratio [HR] ¼ 0.73, 95% confidence interval [CI]: 0.62-0.87, p ¼ 0.0003) in the ITT population, with a median OS time of 13.8 months (95% CI: 11.8-15.7 months) versus 9.6 months (95% CI: 8.6-11.2 months), respectively. 7 An OS benefit with atezolizumab was observed regardless of PD-L1 expression, including in patients with PD-L1 expression on less than 1% of TCs and ICs (TC0 and IC0 subgroup) (HR ¼ 0.75, 95% CI: 0.59-0.96). Patients with the highest PD-L1 expression (TC3 or IC3 subgroup) received the greatest benefit with atezolizumab (HR ¼ 0.41, 95% CI: 0.27-0.64). Atezolizumab was well tolerated, with a favorable safety profile.
Here we report an updated analysis of OAK with an additional 7 months of follow-up in the primary efficacy population (ITT850), as well as an initial analysis of the secondary efficacy population (ITT1225).
Methods

Study Design and Patients
The study design of OAK has been previously reported. 7 Patients had disease progression after one or two previous cytotoxic chemotherapy regimens, including at least one platinum-based therapy, and patients with EGFR or ALK receptor tyrosine kinase gene (ALK) alterations were required to have received approved targeted therapy. All patients provided signed informed consent, and the study was conducted in full accordance with the Guideline for Good Clinical Practice and the Declaration of Helsinki.
Treatment and Assessments
Atezolizumab was administered as an intravenous 1200-mg fixed dose every 3 weeks until loss of clinical benefit as assessed by the investigator in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression. 7 Docetaxel was administered intravenously at 75 mg/m 2 every 3 weeks until unacceptable toxicity or disease progression. 7 Crossover from docetaxel to atezolizumab was allowed after primary analysis demonstrating OS benefit with atezolizumab 7 ; however, no crossover occurred before this updated data cutoff.
Tumor assessments were performed at baseline, then every 6 weeks until week 36, and every 9 weeks thereafter until disease progression per the Response Evaluation Criteria in Solid Tumors version 1.1 or discontinuation of treatment if patients had been receiving atezolizumab beyond progression. 7 After discontinuation of treatment, patients were followed up for survival and subsequent use of nonprotocol therapy. 7 PD-L1 expression was prospectively measured in baseline tumor samples by using the Ventana SP142 immunohistochemistry assay (Ventana Medical Systems, Tucson, AZ) (Supplementary Table 1) . 7 
Outcomes
The primary end point was OS compared between treatment arms within the ITT and the TC1/2/3 or IC1/ 2/3 subgroup for the ITT850, which was initially evaluated as of July 7, 2016. 7 After 7 months of additional follow-up (data cutoff date of January 23, 2017), an updated evaluation of the ITT850 primary population was performed. In addition, the ITT1225 was assessed for differences in OS between treatment arms in the ITT and the TC1/2/3 or IC1/2/3 subgroup in a coprimary fashion, followed by sequential evaluation of the TC2/3 or IC2/3 subgroup (PD-L1 expression on at least 5% of TCs or ICs) and the TC3 or IC3 subgroup. Secondary end points included investigator-assessed progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR). 7 Safety was assessed in all patients who received any dose of the study treatment. The incidence, nature, and severity of adverse events (AEs) and abnormalities in laboratory test results were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. 7 The incidence, nature, and severity of immune-related AEs (irAEs) were analyzed according to a set of comprehensive definitions by using Medical Dictionary for Regulatory Activities Standardized Queries, sponsor-defined AE group terms, and Medical Dictionary for Regulatory Activities-Defined High-Level Terms.
Statistical Analysis
Statistical testing of the OAK secondary population was similar to the primary population analysis previously reported 7 ; a values were recycled from the ITT850 to test OS in the ITT1225 (a ¼ 3%) and TC1/2/3 or IC1/ 2/3 subgroup of the ITT1225 (a ¼ 2%) in a coprimary fashion. If one or both were significant, the a values would be further recycled to test OS sequentially in the TC2/3 or IC2/3 and TC3 or IC3 subgroups of the ITT1225. The secondary OS analysis for the ITT1225 was planned when approximately 75% of patients in this population had died, with concurrent updated analysis of the ITT850. OS was compared between treatment arms with a stratified log-rank test at the two-sided significance level. The Kaplan-Meier approach was used to estimate median OS; the Brookmeyer-Crowley methodology was used to estimate 95% CIs. HRs were estimated with a stratified Cox regression analysis. Prespecified analyses to determine treatment effect by histological type, PD-L1 expression, and other baseline characteristics were performed by using an unstratified Cox regression analysis for estimation of HR. PFS, ORR, and DOR were analyzed by using the same methodologies as in the primary analysis. 7 A post hoc exploratory OS analysis using a rankpreserving structural failure time (RPSFT) model was performed. 9 Confidence intervals for HRs were computed according to previously reported methodology. 10 This sensitivity analysis adjusted for the effect of subsequent nonprotocol immunotherapy received by patients in the docetaxel arm on the observed survival benefit with atezolizumab in the updated ITT850 and ITT1225 populations. Briefly, the survival time of patients in the docetaxel arm who subsequently received nonprotocol immunotherapy was adjusted such that it reflected survival in the absence of any benefit from immunotherapy; patients were recensored to reflect this time adjustment. A Schoenfeld residual test on the calculated counterfactual times confirmed that the proportional hazards assumption in the RPSFT analysis was appropriate for this data set (chi-square result of 1.81 [p ¼ 0.18]).
Results
Updated Efficacy in the OAK ITT850
In the ITT850, 425 patients were randomized to receive atezolizumab and 425 were randomized to receive docetaxel. 7 At the time of the current data cutoff (January 23, 2017), the median follow-up was 28 months (minimum follow-up time of 26 months). The baseline demographics were well balanced between treatment arms.
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The 12-, 18-, and 24-month landmark OS rates with atezolizumab versus with docetaxel were 54.7% versus 41.1%, 40.0% versus 26.9%, and 30.9% versus 21.1%, respectively (Fig. 1A) . The median OS was 13.8 months (95% CI: 11.8-15.7 months) in the atezolizumab arm versus 9.6 months (95% CI: 8.6-11.2 months) in the docetaxel arm. The updated HR with atezolizumab versus docetaxel was 0.75 (95% CI: 0.64-0.89; p ¼ 0.0006). The event-to-patient ratio of the updated analysis increased to 72% from 67% in the primary analysis, 7 representing a slowing rate of patient deaths in both treatment arms.
The survival benefit with atezolizumab versus docetaxel was observed across all PD-L1 expression subgroups defined by different cutpoints for TC or IC expression, including in the subgroup with low or no PD-L1 expression (TC0 and IC0) (HR ¼ 0.77, 95% CI: 0.61-0.97), with the greatest benefit in the high-PD-L1 subgroup (TC3 or IC3) (HR ¼ 0.40, 95% CI: 0.27-0.61) ( Table 1 and Fig. 1B-E) . To evaluate the contribution of individual PD-L1 immunohistochemistry expression strata to efficacy of atezolizumab, OS analyses in the mutually exclusive subgroups were also performed ( Supplementary Fig. 1 ). These data showed improvement in survival with atezolizumab across PD-L1 expression strata, except in the mutually exclusive TC2 or IC2 subgroup (i.e., the TC2/3 or IC2/3 subgroup excluding the TC3 or IC3 subgroup), which had similar OS with atezolizumab and with docetaxel; the median OS in the atezolizumab arm was 12.1 months compared with 14.1 months in the docetaxel arm.
Improvement in survival with atezolizumab was seen both in patients in the nonsquamous subgroup and in patients in the squamous subgroup (HR ¼ 0.74, 95% CI: 0.61-0.89 and HR ¼ 0.77, 95% CI: 0.57-1.03, respectively) ( Fig. 1F and G) . Evaluation of OS according to PD-L1 expression within histological subgroups revealed that increasing survival benefit with increased PD-L1 expression was more evident for patients with nonsquamous histological features than for patients with squamous histological features ( Supplementary Fig. 2 ).
OS HRs favoring atezolizumab were observed across most demographics and baseline characteristic subgroups ( Supplementary Fig. 3 ), including patients with brain metastases at baseline (HR ¼ 0.57, 95% CI: 0.33-0.97) and never-smokers (HR ¼ 0.72, 95% CI: 0.49-1.08), although CIs crossed 1 for several subgroups; patients with EGFR mutation did not show survival benefit with atezolizumab versus with docetaxel (HR ¼ 1.24, 95% CI: 0.71-2.15). Improvement in OS with atezolizumab versus docetaxel was observed across geographical regions in which the largest proportions of patients were enrolled in this global study (see Supplementary Fig. 3 ).
PFS benefit with atezolizumab versus docetaxel was not observed in the updated ITT850 (HR ¼ 0.93, 95% CI: 0.80-1.08) but was observed in the TC2/3 or IC2/3 (HR ¼ 0.76, 95% CI: 0.59-0.99) and TC3 or IC3 subgroups (HR ¼ 0.62, 95% CI: 0.43-0.89). PFS results for the updated ITT850 and PD-L1 expression subgroups are reported in Table 1 . Analysis of mutually exclusive PD-L1 subgroups revealed that PFS benefit was limited to the TC3 or IC3 subgroup (Supplementary Table 2 ). Response rates in the ITT population were similar in the atezolizumab and docetaxel arms (14.6% and 13.4%, respectively) (see Table 1 ), but improvement with atezolizumab versus docetaxel was observed in the TC2/3 or IC2/3 (24.0% versus 12.5%) and TC3 or IC3 subgroups (30.6% versus 10.8%). The rates of response to atezolizumab versus to docetaxel were similar in the TC2/3 or IC2/3 subgroup when the TC3 or IC3 subgroup was excluded (16.9% versus 14.3%) (see Supplementary  Table 2 ). Responses with atezolizumab were durable in the ITT850, with a median DOR of 16.3 months (95% CI: 10.0-26.3 months) versus 6.2 months for docetaxel (95% CI: 4.9-8.4 months). This trend was consistent across PD-L1 expression subgroups (see Table 1 ).
Secondary Population Efficacy Analysis from OAK (ITT1225)
In the ITT1225, 613 patients were randomized to receive atezolizumab and 612 were randomized to receive docetaxel. The median follow-up in the ITT1225 was 26 months (minimum follow-up of 21 months). Baseline demographics were well balanced between the atezolizumab and docetaxel arms in the ITT1225 population (Table 2) .
A survival benefit with atezolizumab versus docetaxel was observed (HR ¼ 0.80, 95% CI: 0.70-0.92, p ¼ 0.0012) ( Fig. 2A) . The median OS with atezolizumab was 13.3 months (95% CI: 11.3-14.9 months) versus 9.8 months (95% CI: 8.8-11.3 months) with docetaxel. The landmark OS rates at 12, 18, and 24 months with atezolizumab versus with docetaxel were 53.0% versus 42.6%, 38.6% versus 28.7%, and 29.7% versus 22.1%, respectively. A survival benefit with atezolizumab versus docetaxel was observed across prespecified PD-L1 expression subgroups, including the TC1/2/3 or IC1/2/3 subgroup (HR ¼ 0.77, 95% CI: 0.64-0.92), with the greatest benefit in the TC3 or IC3 subgroup (HR ¼ 0.45, 95% CI: 0.30-0.68) (see Table 1 and Fig. 2B-E ITT850 population (see Supplementary Fig. 1 ). A survival benefit with atezolizumab was observed across histological types, with an HR of 0.79 for patients with nonsquamous or squamous NSCLC ( Fig. 2F and G) ; improved OS with atezolizumab versus docetaxel was observed across PD-L1 expression subgroups in both histological subgroups, with a more pronounced increase in benefit with increasing PD-L1 expression observed in patients in the nonsquamous subgroup than in patients in the squamous subgroup (see Supplementary Fig. 2 ). OS benefit with atezolizumab versus docetaxel was observed across most demographic and baseline characteristic subgroups and geographical regions and was generally consistent with that in the ITT850 (see Supplementary Fig. 3 ).
No PFS benefit for atezolizumab versus docetaxel was observed in the ITT1225 population (HR ¼ 0.96, 95% CI: 0.85-1.08) (see Table 1 and Supplementary Fig. 4A ). However, PFS benefit with atezolizumab was observed in patients with high PD-L1 expression, including in both the TC2/3 or IC2/3 and TC3 or IC3 subgroups (see Table 1 and Supplementary Fig. 4B-E) . ORR per the Response Evaluation Criteria in Solid Tumors version 1.1 was comparable in the atezolizumab and docetaxel arms (13.7% and 11.8%, respectively) (see Table 1 ). Higher response rates with atezolizumab versus docetaxel were observed in the TC2/3 or IC2/3 (25.0% versus 11.0%) and TC3 or IC3 (31.5% versus 9.4%) subgroups. Atezolizumab continued to show a PFS benefit and increased ORR versus docetaxel upon exclusion of the TC3 or IC3 subgroup from the TC2/3 or IC2/3 subgroup compared with the TC2/3 or IC2/3 subgroup (see Supplementary Table 2 and Table 1 ). Atezolizumab demonstrated a longer median DOR versus docetaxel (23.9 months [95% CI: 12.8 months-not Note: Expression levels for the subgroups were as follows: TC3 or IC3, PD-L1 expression on at least 50% of TCs or at least 10% of ICs; TC2/3 or IC2/3, PD-L1 expression on at least 5% of TCs or ICs; TC1/2/3 or IC1/2/3, PD-L1 expression on at least 1% of TCs or ICs; TC0 and IC0, PD-L1 expression on less than 1% of TCs and ICs. The data cutoff date was January 23, 2017. a Stratified HR for ITT850 and ITT1225. Unstratified HR for ITT850 and ITT1225. OS, overall survival; PFS, progression-free survival; ORR, objective response rate; DOR, duration of response; ITT, intention-to-treat; ITT850, primary efficacy population; ITT1225, secondary efficacy population; PD-L1, programmed death-ligand 1; HR, hazard ratio; CI, confidence interval; TC, tumor cell; IC, tumorinfiltrating immune cell; NE, not estimable. estimable] versus 6.3 months [95% CI: 5.5-7.6 months], respectively). The median DOR was consistent across PD-L1 expression subgroups (see Table 1 ).
Subsequent Nonprotocol Immunotherapy and RPSFT Analysis
More patients in the docetaxel arm of the ITT1225 analysis received subsequent immunotherapy (in particular, nivolumab) as a nonprotocol therapy (23.0%) than did patients in the docetaxel arm of the updated ITT850 (18.4%) (Supplementary Table 3 ). Subsequent immunotherapy was received by 33.7% of the patients in the docetaxel arm among the last 375 patients enrolled, including 45% of the TC3 or IC3 subgroup in this population.
Because of the known OS benefit provided by PD-L1/PD-1 checkpoint inhibitors in this treatment setting, 11, 12 a sensitivity analysis was performed to examine the impact of subsequent immunotherapy use in the docetaxel arm on the observed comparative survival benefit with atezolizumab. When the RPSFT model was used to adjust for subsequent exposure to immunotherapy, the HR favoring atezolizumab versus docetaxel was mildly reduced in both analysis populations compared with the conventionally censored OS (HR ¼ 0.69 versus 0.75 for ITT850 and HR ¼ 0.74 versus 0.80 for ITT1225). This reduction arose primarily from a decrease in the median OS in patients in the docetaxel arm as a result of RPSFT censoring versus conventional censoring (9.3 versus 9.6 months in the ITT850 and 9.5 versus 9.8 months in the ITT1225) ( Table 3 and Supplementary Fig. 5 ).
Updated Safety Analysis
The safety population comprised 609 patients who received atezolizumab and 578 patients who received docetaxel (Table 4 ). More patients in the atezolizumab arm continued to receive treatment for more than 1 year than did patients in the docetaxel arm (20.5% versus 2.4%). For those patients in the atezolizumab arm who experienced disease progression, 169 of 338 patients (50.0%) in the ITT850 and 238 of 482 patients (49.4%) in the ITT1225 continued treatment beyond disease progression. The median duration of treatment in patients in the atezolizumab arm was 3.4 months (range 0-32 months) versus 2.1 months (range 0-30 months) in the docetaxel arm.
The incidence of treatment-related AEs (trAEs) was 64.0% with atezolizumab and 86.2% with docetaxel. Grade 3 or 4 trAEs occurred in 14.9% of patients receiving atezolizumab and 42.4% of patients receiving docetaxel. trAEs leading to withdrawal of the study drug occurred in 7.9% of patients receiving atezolizumab. No grade 5 trAEs were reported in patients receiving atezolizumab.
The incidence of irAEs with atezolizumab was 33.2% (Supplementary Table 4 ). The most common Note: Expression levels for the subgroups were as follows: TC3 or IC3, PD-L1 expression on at least 50% of TCs or at least 10% of ICs; TC2/3 or IC2/3, PD-L1 expression on at least 5% of TCs or ICs; TC1/2/3 or IC1/2/3, PD-L1 expression on at least 1% of TCs or ICs; TC0 and IC0, PD-L1 expression on less than 1% of TCs and ICs. The data cutoff date was January 23, 2017. a Includes American Indian, Alaskan Native, Hawaiian Native, other Pacific Islander, other, and multiple. ITT, intention-to-treat; ITT1225, secondary efficacy population; ECOG PS, Eastern Cooperative Oncology Group performance status; EML4-ALK, echinoderm microtubule associated protein like 4 gene-ALK receptor tyrosine kinase gene; PD-L1, programmed death-ligand 1; TC, tumor cell; IC, tumorinfiltrating immune cell.
immune-related category was rash (16.9%), with most being grade 1 or 2. The second most commonly reported category was hepatitis, specifically, abnormal liver function test results, including increased aspartate aminotransferase levels (all grades, 6.7%; grade 3 or 4, 1.3%) and increased alanine aminotransferase levels (all grades, 5.9%; grade 3 or 4, 1.0%). Other categories of irAEs included hypothyroidism (4.8%) and pneumonitis (2.3%).
Discussion
Inhibitors of the PD-L1/PD-1 pathway (e.g., atezolizumab, nivolumab, and pembrolizumab) have become recommended treatment options for patients with second-line or later NSCLC. This updated analysis of OAK, which is the largest study conducted with an anti-PD-L1 or anti-PD-1 immunotherapy in this setting, reaffirmed the efficacy of atezolizumab compared with that of docetaxel and demonstrated consistency with the primary analysis 7 after longer follow-up. The survival benefit with atezolizumab was maintained in the ITT850 and across PD-L1 expression subgroups and NSCLC histological subgroups.
Mutually exclusive analyses suggest that the enhanced benefit in the TC2/3 or IC2/3 subgroup was driven by patients with TC3 or IC3, and the high HR in the mutually exclusive TC2 or IC2 subgroup might imply that these patients do not experience an OS benefit with atezolizumab relative to docetaxel. However, evaluation of the performance of the atezolizumab arm and docetaxel control arm across mutually exclusive groups revealed that this result may be driven by the anomalously high OS for the docetaxel arm in the mutually exclusive TC2 or IC2 group (median OS of 14.1 months), whereas OS in the atezolizumab arm was similar to that seen in the ITT850. These observations, coupled with the benefit observed at the low end of the PD-L1 expression spectrum (in the TC0 and IC0 subgroup), implies that the result for the mutually exclusive TC2 or IC2 subgroup was an outlier and that atezolizumab provides a survival benefit across all levels of PD-L1 expression, with pronounced benefit limited to the TC3 or IC3 subgroup.
The analysis of the secondary efficacy population from OAK (ITT1225) demonstrated largely consistent efficacy with atezolizumab versus docetaxel relative to that in the primary efficacy population, with a slightly increased HR point estimate. A survival benefit with atezolizumab versus docetaxel was observed in both nonsquamous and squamous NSCLC, and the OS trends with atezolizumab were similar across PD-L1 expression subgroups, including in patients with low or no PD-L1 expression, with a greater benefit in patients with high PD-L1 expression. Furthermore, OS trends in the baseline characteristic subgroups were maintained in the ITT1225, except for a decrease in the comparative survival benefit in never-smokers. Patients with brain metastases at baseline continued to show benefit with atezolizumab. Efficacy in this subpopulation is relevant in view of the relatively high prevalence of brain metastases in NSCLC. [13] [14] [15] With regard to molecular subtypes, patients with EGFR mutations did not show any benefit with atezolizumab relative to that with docetaxel, which is consistent with previously observed trends with PD-L1/PD-1 blocking agents, 7, 11, 16 and potentially reflecting decreased immunogenicity due to lower tumor mutation burden (TMB), as reported previously, 17 as well as overall lower PD-L1 prevalence in these patients (data not shown, manuscript in preparation). Testing of patients for KRAS mutations was not required in the study protocol; therefore, most patients had unknown KRAS mutation status, possibly because of the variability in mutation screening protocols across study sites. Although a minority of patients had known KRAS mutation status, those with known KRAS mutations showed an OS HR point estimate similar to that of patients with KRAS wild type (WT) or patients with unknown KRAS status. Previous reports suggested that patients with KRAS mutations have a TMB similar to that of patients with KRAS WT 17 ; therefore, both patient populations should be characterized by a similar immunogenicity. This may potentially explain why patients with KRAS mutations derived a benefit from atezolizumab similar to that derived by patients with KRAS WT. Too few patients with known ALK rearrangement-positive tumors were enrolled to allow evaluation of efficacy with PD-L1 blockade in this subgroup. Other predictive biomarkers for the clinical activity of atezolizumab are currently being investigated, including TMB (both in tumor tissue and in blood) and T-effector gene signature. 18, 19 These analyses may also help to better understand a complex tumor immune biology behind the efficacy of cancer immunotherapy and help to explain why some patients with PD-L1-negative tumors derive benefit from treatment with atezolizumab.
The increased availability and use of checkpoint inhibitors in this patient population over the course of the OAK study had the potential to affect measured survival benefit with atezolizumab owing to the expected OS benefit in patients in the docetaxel arm who were receiving these therapies during survival follow-up. 11, 12 As expected, more patients in the docetaxel arm received immunotherapy as nonprotocol therapy in the ITT1225 than in the ITT850, reflecting the increased use of checkpoint inhibitors among the last 375 patients enrolled at the end of the study recruitment period. The improved OS benefit with atezolizumab compared with conventional OS estimates seen in the sensitivity analysis suggests that increased subsequent immunotherapy use may have improved OS in the docetaxel arm. Furthermore, the increased use of immune checkpoint inhibitors among patients who were enrolled later during study recruitment may explain the modest increase (approximately 1%-2%) in 12-, 18-, and 24-month landmark OS rates in the docetaxel arm in the ITT1225, which potentially translates to the increased HR observed in this population.
PFS and ORR did not capture the entire clinical benefit with atezolizumab versus docetaxel in both the ITT850 and ITT1225 populations, although efficacy of atezolizumab measured by these end points was enriched in patients with high tumor PD-L1 expression. This is consistent with the primary analysis 7 and observations from the phase II POPLAR study, 8 as well as with the results from studies of other inhibitors of the PD-L1/PD-1 pathway. 11, 12, 16 The OS benefit without PFS benefit in patients with lower levels of PD-L1 expression might be indicative of postprogression prolongation of survival. 20 Although the mechanism of postprogression effects is not clear, continued clinical benefit may be associated with treatment with atezolizumab beyond radiographic progression, 20 which occurred frequently across both ITT populations. Furthermore, the responses to atezolizumab were durable in both populations, with 50% of responses ongoing in the ITT1225.
Atezolizumab continued to demonstrate a favorable safety profile compared with that of docetaxel after extended follow-up. The incidences and nature of trAEs and irAEs with atezolizumab after longer exposure to treatment were similar to those seen in the primary analysis. 7 The rates of grade 3 or 4 trAEs and irAEs remained low.
This updated analysis encompasses a large study population that is representative of patients with second-line or third-line NSCLC across both nonsquamous and squamous subgroups with relatively mature survival follow-up. Given the durability of response and extended survival observed in some patients receiving atezolizumab, additional follow-up will be of interest to better evaluate long-term survivors. Characteristics of these long-term survivors from OAK are currently under investigation. 21 Overall, this updated and expanded follow-up of the phase III OAK study demonstrated consistent survival benefit with atezolizumab versus docetaxel in second-line or later NSCLC, with extended exposure to atezolizumab being well tolerated.
